The New Product Planning Summit reinforces product development and value creation, encourages strategic product development, and provides insights into gaining key stakeholder buy-in for a successful launch and commercialization of new products.
Doug Willson, Principal at Viscadia, will be a member of the speaking faculty at the event.
Industry executives agree that the Inflation Reduction Act (IRA) has significant potential to impact the value of biopharmaceutical assets and portfolios. However, there is also a significant amount of uncertainty regarding the ultimate impact of the IRA and how markets will evolve over time. The effects of the IRA are complex, differing across therapeutic categories, types of molecules, stages of development and other factors. New product planning teams are faced with the immediate need to revisit forecasts for pipeline and inline products, as well as evaluate a variety of possible scenarios and contingencies.
Industry executives agree that the Inflation Reduction Act (IRA) has significant potential to impact the value of biopharmaceutical assets and portfolios. However, there is also a significant amount of uncertainty regarding the ultimate impact of the IRA and how markets will evolve over time. The effects of the IRA are complex, differing across therapeutic categories, types of molecules, stages of development and other factors. New product planning teams are faced with the immediate need to revisit forecasts for pipeline and inline products, as well as evaluate a variety of possible scenarios and contingencies.
Viscadia is a platinum sponsor at the event.
To learn more please feel free to reach out to us at info@viscadia.com.
© 2023 Viscadia Inc. All Rights Reserved. Privacy Policy Terms of Use
